newsfilter
← Latest News
Business Wire·

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on